Svennerholm Ann-Mari, Steele Duncan
Department of Medical Microbiology and Immunology, and Göteborg University Vaccine Institute (GUVAX), Göteborg University, P.O. Box 435, Göteborg S-405 30, Sweden.
Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):421-45. doi: 10.1016/j.bpg.2003.11.004.
Enteric infections resulting in diarrhoea are among the most important causes of morbidity and mortality, particularly in children in developing countries. They are also a common cause of disease among travellers to Africa, Asia and Latin America. Recently, effective, live and inactivated oral and parenteral vaccines against some of the most severe enteric infections-cholera and typhoid fever-have been licensed in several countries. Different candidate vaccines against rotavirus, Shigella and ETEC diarrhoea have also been developed and tested for safety and immunogenicity in developed as well as in developing countries. The protective efficacy of several of these vaccines has also been tested, either in human volunteer challenge studies or in field trials. In this chapter we describe the properties and availability of the recently licensed vaccines and present an update on the diverse efforts being made to achieve new or improved vaccines against the most prevalent enteropathogens.
导致腹泻的肠道感染是发病和死亡的最重要原因之一,在发展中国家的儿童中尤为如此。它们也是前往非洲、亚洲和拉丁美洲的旅行者中常见的疾病病因。最近,针对一些最严重的肠道感染——霍乱和伤寒热——的有效、活疫苗、灭活疫苗以及口服和注射用疫苗已在多个国家获得许可。针对轮状病毒、志贺氏菌和产肠毒素大肠杆菌性腹泻的不同候选疫苗也已研发出来,并在发达国家和发展中国家进行了安全性和免疫原性测试。其中几种疫苗的保护效力也已在人体志愿者激发试验或现场试验中进行了测试。在本章中,我们描述了最近获得许可的疫苗的特性和可及性,并介绍了为研发针对最常见肠道病原体的新疫苗或改进疫苗所做的各种努力的最新情况。